Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 3
1967 20
1968 32
1969 70
1970 83
1971 92
1972 86
1973 86
1974 118
1975 86
1976 60
1977 79
1978 64
1979 104
1980 78
1981 103
1982 147
1983 155
1984 220
1985 224
1986 231
1987 221
1988 312
1989 438
1990 409
1991 437
1992 445
1993 507
1994 519
1995 556
1996 533
1997 535
1998 570
1999 689
2000 621
2001 712
2002 770
2003 743
2004 867
2005 827
2006 842
2007 1104
2008 1295
2009 1321
2010 1513
2011 1927
2012 2528
2013 2752
2014 2944
2015 2839
2016 2363
2017 2340
2018 2377
2019 1242
2020 40
Text availability
Article attribute
Article type
Publication date

Search Results

36,123 results
Results by year
Filters applied: . Clear all
Page 1
Meta-analysis of postoperative adjuvant therapy for small bowel adenocarcinoma.
Ye X, et al. PLoS One 2018 - Review. PMID 30096150 Free PMC article.
OBJECTIVE: The role of adjuvant therapy in small bowel adenocarcinoma (SBA), a rare malignancy with a poor prognosis, is controversial. ...Further, 607 patients with duodenal adenocarcinoma (DA) had similar results (pooled HR = 0.96, 95% CI = 0.75-1.23, p = 0.77). ...
OBJECTIVE: The role of adjuvant therapy in small bowel adenocarcinoma (SBA), a rare malignancy with a poor prognosis, is controversia …
Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis.
Boland JM, et al. Hum Pathol 2018. PMID 28823574
Invasive mucinous adenocarcinoma is a variant of lung adenocarcinoma, which may be mixed with nonmucinous adenocarcinoma. KRAS mutations are common, but other clinical and genetic features are not clearly established. ...Pulmonary invasive mucinous adenocarcinomas and mixed nonmucinous/mucinous adenocarcinomas are clinically and genetically similar, except for a higher rate of ALK rearrangement in mixed tumors. ...
Invasive mucinous adenocarcinoma is a variant of lung adenocarcinoma, which may be mixed with nonmucinous adenocarcinoma
Impact of Barrett's esophagus surveillance on the prognosis of esophageal adenocarcinoma: A meta-analysis.
Ding YE, et al. J Dig Dis 2018. PMID 30375167
OBJECTIVE: Whether endoscopic surveillance would improve the outcomes of esophageal adenocarcinoma in patients previously diagnosed with Barrett's esophagus remains unclear. ...Compared with patients with esophageal adenocarcinoma that was not detected by surveillance, a significant 29% reduction in mortality from esophageal adenocarcinoma was observed among patients under endoscopic surveillance (adjusted hazard ratio [HR] 0.71, 95% CI 0.66-0.77). ...
OBJECTIVE: Whether endoscopic surveillance would improve the outcomes of esophageal adenocarcinoma in patients previously diagnosed w …
Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer.
Kao YC, et al. Gastric Cancer 2019. PMID 30069742
RESULTS: The overall incidence of signet ring cell adenocarcinoma was 25.4%. Our results showed that the 5-year overall survival rates of early gastric cancer patients with signet ring cell adenocarcinoma and non-signet ring cell adenocarcinoma were 90.7 and 83.2%, respectively (P = 0.001). ...The 5-year overall survival rates of advanced gastric cancer patients with signet ring cell adenocarcinoma and non-signet ring cell adenocarcinoma were 32.1 and 37.9%, respectively (P = 0.041). ...
RESULTS: The overall incidence of signet ring cell adenocarcinoma was 25.4%. Our results showed that the 5-year overall survival rate …
Pancreas adenocarcinoma: novel therapeutics.
Krantz BA, et al. Chin Clin Oncol 2017. PMID 28705007 Free article.
Pancreatic ductal adenocarcinoma (PDAC) is the third highest cause of cancer-related deaths in the US, and is projected to be second only to non-small cell lung cancer (NSCLC) by the 2020s. ...
Pancreatic ductal adenocarcinoma (PDAC) is the third highest cause of cancer-related deaths in the US, and is projected to be second …
A Competing-Risks Nomogram in Patients with Metastatic Pancreatic Duct Adenocarcinoma.
Lu Y, et al. Med Sci Monit 2019. PMID 31102397 Free PMC article.
BACKGROUND The primary objective of this study was to assess the cumulative incidence of cause-specific mortality (CSM) and other causes of mortality (OCM) for patients with metastatic pancreatic duct adenocarcinoma (mPDAC). ...We assessed the cumulative incidence function (CIF) for cause-specific mortality and other causes of mortality. We used Gray's test to investigate the differences. ...
BACKGROUND The primary objective of this study was to assess the cumulative incidence of cause-specific mortality (CSM) and other cau …
36,123 results
Jump to page
Feedback